
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is poised for strong long-term growth as their ABC platform has shown robust results in both their investigational medicines, tarcocimab and KSI-501. The successful GLOW2 trial in DR validates the reformulated design and supports its potential for addressing current anti-VEGF limitations. With multiple pivotal data readouts expected in 2026 and 2027, Kodiak Sciences has the potential to become a leader in the treatment of retinal diseases.
Bears say
Kodiak Sciences is a high-risk investment due to their reliance on the success of their investigational medicines, especially tarcocimab, which is expected to face competition from other anti-VEGF therapies. Additionally, the company may need to raise additional capital before achieving profitability, potentially resulting in share dilution for shareholders. Furthermore, there are potential clinical and regulatory risks associated with the development and approval of their pipeline products, which could lead to delays or failure. Risks aside, Kodiak's financial data suggests a reliance on external funding sources until at least 2027, which could impact their financial health and negatively affect their valuation.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares